SeaStarMedical (@SeaStarMedical) / X

SeaStarMedical

411 posts

SeaStarMedical

@SeaStarMedical

Medical technology company working to reduce the consequences of hyperinflammation on organs with cell-directed extracorporeal therapies.

Joined October 2020

SeaStarMedical
@SeaStarMedical
May 24, 2022
We are excited to announce that Dr. Kevin Chung will join SeaStar Medical as Chief Medical Officer, effective July 1, 2022. Dr. Chung is a renowned critical care physician and expert in extracorporeal life support therapies. Read more at hubs.li/Q01b_GtC0
SeaStarMedical
@SeaStarMedical
Feb 22, 2024
PRESS RELEASE: FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury Read the full release HERE: investors.seastarmedical.com/news/news-deta… #medicalnews #PressRelease #medicaldevice $ICU
21K
SeaStarMedical
@SeaStarMedical
Feb 8, 2024
Here’s a short video of what we’re fighting against in acute kidney injury here at SeaStar Medical. youtu.be/Wn-7RfRQr20?si… Next week, we’ll show you what we’re doing about it….stay tuned! #Healthcare #AKI #SeaStar $ICU
17K
SeaStarMedical
@SeaStarMedical
Mar 4, 2024
Big news from the Big Apple – read more from the official @US_FDA website HERE: fda.gov/vaccines-blood… Thank you @Nasdaq for the great shot! #fdaapproval #nasdaq #icu $ICU
10K
SeaStarMedical
@SeaStarMedical
Mar 1, 2024
Watch the exciting and informative interview from our fearless leader, CEO Eric Schlorff @SchlorffEric as he discusses SeaStar Medical on the Big Biz Show! @SullyOnTheAir @SullySpeaks @biztv @biztalkradio @youtooamerica
00:00
3.5K
SeaStarMedical
@SeaStarMedical
Feb 23, 2024
It’s been a big week here at SeaStar Medical! In addition to the approval of our Quelimmune (SCD-Pediatric) device, we’ve also published a significant manuscript highlighting the robust capabilities of this novel technology: Stu Goldstein’s @slgold777 paper showcasing the pooled
6.7K
SeaStarMedical
@SeaStarMedical
Feb 14, 2024
Last week, we shared what we’re fighting against in acute kidney injury here at SeaStar Medical – this week, we’re excited to share how we are combating this harmful disease with the Selective Cytopheretic Device (SCD). LINK: youtu.be/6jrCjJkdzZo?si… #healthcare #AKI
7.4K
SeaStarMedical
@SeaStarMedical
May 20, 2024
SeaStar CEO, @SchlorffEric appears on the Big Biz Show to discuss our SCD technology and progress we're making to commercialize the QUELimmune pediatric device! Big things ahead!! #SCD $ICU #ICU @SullyOnTheAir
00:00
3.9K
SeaStarMedical
@SeaStarMedical
Feb 27, 2024
PRESS RELEASE: Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure Read the full release HERE: investors.seastarmedical.com/news/news-deta… #pressrelease #medicalnews
4.1K
SeaStarMedical
@SeaStarMedical
Feb 28, 2024
In this newly published paper, led by Dr. Jeffrey Dellavolpe and team, read about the role our SCD played in a groundbreaking sequential extracorporeal treatment strategy of a 28-year-old patient who developed streptococcal toxic shock syndrome with multi-organ failure.
6.4K
SeaStarMedical
@SeaStarMedical
Jun 30, 2022
We welcome @chungk1031 as Chief Medical Officer of SeaStar Medical. His 20+ years as a critical care physician with expertise in extracorporeal life support therapies (ECLS) will help drive higher standards of care for critically ill patients. Welcome to SeaStar Medical, Kevin.
SeaStarMedical
@SeaStarMedical
Mar 18, 2024
SeaStar is a proud sponsor of the 6th CKD Drug Development Summit, taking place March 19-21 in Boston. The CKD Summit is the premier forum bringing together key opinion leaders, industry partners and regulators focusing on the next generation of drug development in kidney
3K
SeaStarMedical
@SeaStarMedical
Oct 30, 2023
PRESS RELEASE: FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Patients Read the full release HERE: investors.seastarmedical.com/news/news-deta… #seastar #medical #pressrelease #pediatrics #biotech #ICU $ICU
4K
SeaStarMedical
@SeaStarMedical
Mar 12, 2024
PRESS RELEASE: SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients Read the full release HERE: investors.seastarmedical.com/news/news-deta… #MedTwitter #SCDPED #AKI #ICU $ICU
3K